Golimumab for the treatment of ulcerative colitis

@inproceedings{Loewenberg2014GolimumabFT,
  title={Golimumab for the treatment of ulcerative colitis},
  author={M. L. Loewenberg and Frank Hoentjen},
  booktitle={Clinical and experimental gastroenterology},
  year={2014}
}
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel… CONTINUE READING
2
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease

  • International journal of molecular sciences
  • 2017
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

RD Inman, JC JrDavis, D Heijde
  • Arthritis Rheum. 2008;58:3402–3412
  • 2014
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…